Register
Login:
Share:
Email Facebook Twitter




Quick Poll
QUICK POLL >
Would you use a professional standard news service? (Giving you breaking news sooner)




Add Futura Medical to quick picks

Futura Medical Share Price (FUM)



Share Price Information for Futura Medical (FUM)


Share Price: 40.00Bid: 39.00Ask: 41.00Change: 0.00 (0.00%)No Movement on Futura Med.
Spread: 2.00Spread as %: 5.13%Open: 40.75High: 40.75Low: 40.00Yesterday’s Close: 40.00
InfoCFDs vs Share Trading - Download your Free Guide from London South East Markets
When trading CFDs, Forex, and Spread bets, it is possible to lose more than your initial deposit.


Futura Medical Plc Ord 0.2P

Futura Medical is listed in the FTSE AIM All-Share
Futura Medical is part of the Pharmaceuticals & Biotechnology sector






Share Price SpacerPrice
40.00

Share Price SpacerBid
39.00

Share Price SpacerAsk
41.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
77,919

Share Price SpacerOpen
40.75

Share Price SpacerHigh
40.75

Share Price SpacerLow
40.00

Share Price SpacerClose
40.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 99.02m £39.61m 7,500

52 Week High 68.75 52 Week High Date 2-MAY-2014
52 Week Low 26.25 52 Week Low Date 21-JAN-2015

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
7 77,919 0 -11.940 -3.35 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

17-Apr-15
16:16:25
40.00
125,000
 
39.00
41.00
50.00k
Trade Type:
Ordinary

17-Apr-15
15:37:12
39.0001
5,000
Sell* 
39.00
41.50
1,950
Trade Type:
Ordinary

17-Apr-15
14:49:04
39.0001
2,000
Sell* 
39.00
41.50
780.00
Trade Type:
Ordinary


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Futura Medical trades >>

Directors Deals for Futura Medical (FUM)
Trade DateActionNotifierPriceCurrencyAmountHolding
05-Jan-15Buy
Trade Notifier Information for Futura Medical
John M Clarke held the position of Non-Executive Chairman at Futura Medical at the time of this trade.
 John M Clarke
63.25GBX23,43176968
05-Jan-15Buy
Trade Notifier Information for Futura Medical
Jonathan David Freeman held the position of Senior Independent Non-Executive Director at Futura Medical at the time of this trade.
 Jonathan David Freeman
63.25GBX7,46222382
05-Jan-15Buy
Trade Notifier Information for Futura Medical
Lisa Arnold held the position of Independent Non-Executive Director at Futura Medical at the time of this trade.
 Lisa Arnold
63.25GBX9,49926999
View more Futura Medical directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Tue 18:02
Leveraged
Stats from bluediamondcondom site
41.00
No Opinion

http://bluediamondcondom.com/clinically-proven-through-science/ Blue diamond® condoms have been clinically proven to maximize firmness and hardness by stimulating blood flow within the penis. In an independently conducted study comparing blue diamond® condoms against a standard condom, 74% of men who expressed a preference between the two condoms said that the blue diamond® condom gave them a firmer erection. In the same study 72% of the female partners who expressed a preference also noticed an increase in the firmness of their partner’s penis and 63% felt that as a result of their partner using the blue diamond® condom they enjoyed a longer lasting sexual experience.
Tue 16:49
Johnmeladdy
UK publicity begining
41.00
No Opinion

Spot the flaws in those stats, I am sure they are correct but read between the lines - the fine detail They don't tell you nothing but don't they sound good.
10 Apr '15
Leveraged
UK publicity beginning
41.00
No Opinion

http://forevertourist.co.uk/what-are-the-differences-between-blue-diamond-and-viagra/
3 Apr '15
Chrisjc
Share price
40.50
No Opinion

It's interesting that investors are now starting to recognise what an incredible portfolio this company has! The scenario that goldust88 puts forward doesn't just apply to a single product, Futura has several which have similar possibilities. Buy, buy, buy as at 40p it's a steal . . . . . . . .
1 Apr '15
stumpy10
henderson global
40.50
No Opinion

Looks like they are slowly building a substantial position. Now above 16% nice to see the professionals taking an interest.this share will suddenly bloom maybe sooner than later
29 Mar '15
goldust88
Pain relief products-the winner ?
41.25
No Opinion

from iii Futura advised that the pain relief portfolio has recieved interest from all the major pharmacuetical companies but they were not negotiating with them until after the trials which they are very confident would confirm the effectiveness of the product. It seems to me that this could be even more exciting than CSD and when results are out-June/July a bidding war may be on the cards for the rights. Its quite possible that this could raise more money than the current market capital of the company. Or even 2-3 times that. Voltarol the rights to which it would be competing against was valued at $129 million dollars. See http://www.wikinvest.com/stock/Endo_Pharmaceuticals_Holdings_%28ENDP%29/Novartis Under the terms of the five-year Voltaren® Gel Agreement, Endo made an upfront cash payment of $85 million. Endo has agreed to pay royalties to Novartis AG on annual Net Sales of the Licensed Product, subject to certain thresholds as defined in the Voltaren® Gel Agreement. In addition, Endo has agreed to make certain guaranteed minimum annual royalty payments of $30 million per year payable in the fourth and fifth year of the Voltaren® Gel Agreement, subject to certain limitations as defined in the Voltaren® Gel Agreement. These guaranteed minimum royalties will be creditable against royalty payments on a Voltaren® Gel Agreement year basis such that Endo’s obligation with respect to each Voltaren® Gel Agreement year is to pay the greater of (i) royalties payable based on annual net sales of the Licensed Product or (ii) the guaranteed minimum royalty for such Voltaren® Gel Agreement year. No royalty payments were payable to Novartis during the three months ended March 31, 2009 or 2008. Novartis is also eligible to receive a one-time milestone payment of $25 million if annual net sales of Voltaren® Gel exceed $300 million in the U.S. The $85 million upfront payment and the present value of the guaranteed minimum royalties have been capitalized as an intangible asset in the amount of $129.0 million, representing the fair value of the exclusive license to market Voltaren® That's a lot of money!

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Futura Medical (FUM) >>
Please Login or Register to post messages



Futura Medical Plc Ord 0.2P home pageWebsite: Futura Medical Plc Ord 0.2P
Website Description: Welcome to Futura Medical



Sign up for Live Prices


CD02WL.001.081313


Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.